Indication: For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema
Pharmacology: Ipratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.
Mechanism Of Action: Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.
Drug Category: Bronchodilator Agents; Cholinergic Antagonists; Antimuscarinics; Antispasmodics; ATC:R01AX03; ATC:R03BB01
Absorption: Inhalation (local)-minimal; Nasal-rapid and minimal
Interactions:
DrugBank: Interactions for Ipratropium
Interactions for Ipratropium:
ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic
bronchodilators, methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary
disease. With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of
ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness.
Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation,
there is some potential for an additive interaction with concomitantly used anticholinergic medications. Caution is
therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing
drugs.
Chemical IUPAC Name: [8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]oct-3-yl]3-hydroxy-2-phenyl-propanoate
Chemical Formula: C20H30NO3
Half Life: ~2 hours
Drug Type: Approved Drug
# Accession No: APRD00537
CAS Registry Number: 60205-81-4
Ipratropium News (When available)
Expert works to fix drug development15 Jan 2006 Arizona Republic, ...will track patients on two drugs that treat lung disease: Atrovent, approved 10 years ago by the FDA, and Spiriva, which was approved in 2004. ...
Health NewsDec 20, 2005 Hampton Union, ...qualify. If you take Flovent, Combivent, Proventil, Advair, Pulmicort, Serevent, Atrovent or any other inhaler, the program may help. ...
Bashas', C-Path join FDA studyDec 14, 2005 Arizona Daily Star, The initial program will study patients on two drugs that treat lung disease: Atrovent, which was approved a decade ago, and Spiriva, which was approved in 2004 ...
James Le Fanu investigates some pillow ploys for runny nosesJan 9, 2006 Telegraph.co.uk, ...person, is usually due to an imbalance in the nerves that control the blood flow to the nasal lining, and will respond to the nasal spray Ipratropium Bromide.
Home
Copyright phasechange.org 2006.
All Rights Reserved.
